Steris PLC (NYSE:STE) insider Michael J. Tokich sold 34,500 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $119.16, for a total transaction of $4,111,020.00. Following the sale, the insider now owns 64,958 shares in the company, valued at $7,740,395.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Steris stock traded up $0.81 on Thursday, hitting $120.70. The company’s stock had a trading volume of 521,422 shares, compared to its average volume of 373,073. Steris PLC has a 52-week low of $82.88 and a 52-week high of $121.67. The company has a quick ratio of 2.02, a current ratio of 2.63 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $9.93 billion, a PE ratio of 29.08 and a beta of 1.03.
Steris (NYSE:STE) last released its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported $1.10 EPS for the quarter, topping the consensus estimate of $1.08 by $0.02. Steris had a net margin of 11.72% and a return on equity of 12.15%. The business had revenue of $679.00 million for the quarter, compared to analyst estimates of $659.14 million. During the same period in the previous year, the firm earned $0.94 EPS. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, research analysts expect that Steris PLC will post 4.71 EPS for the current fiscal year.
Several brokerages have commented on STE. Zacks Investment Research lowered shares of Steris from a “hold” rating to a “sell” rating in a research report on Monday, August 6th. KeyCorp boosted their target price on shares of Steris from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 9th. JMP Securities boosted their target price on shares of Steris from $113.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 9th. Finally, Stephens restated a “buy” rating and set a $125.00 target price on shares of Steris in a research report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $100.86.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Article: Why is Cost of Capital Important?
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.